EPO upholds Fujian Cosunter’s C-Met inhibitor patent over Merck’s opposition
MLex Summary: The Boards of Appeal of the European Patent Office have upheld Fujian Cosunter Pharmaceutical's patent for a C-Met inhibitor, dismissing the opposition filed by Merck Patent. The appeal body...To view the full article, register now.
Already a subscriber? Click here to view full article